In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BP PLC

www.bp.com

Latest From BP PLC

Deal Statistics Quarterly, Q4 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case October to Decemeber 2001. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
BioPharmaceutical Medical Device

ThirdWave Pushes for Parity

Third Wave Technologies wants its Invader technology to be as ubiquitous as PCR. Since a deal with potential buyer Applera fell through two years ago, the company has begun several high-profile collaborations, including one with the Japanese SNP initiative, which now accounts for 50% of revenues. Its efforts appear to be paying off, but the company is fighting an uphill battle in an intensely competitive field.
Medical Device Middle East and Africa

Deal Statistics Quarterly, Q3 2001

In Vivo presents another installment of our quarterly review of dealmaking--in this case July 2001-September 2001. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.
BioPharmaceutical Medical Device

Stepping Into the Race to Detect Fetal Cells in Maternal Blood

Many companies have tried and failed to develop tools that could detect fetal cells in maternal blood. Their aim would be to detect pre-natal abnormalities more accurately and earlier than existing tests and to replace invasive methods, such as amniocentesis. Roche Diagnostics started a program in this field six years ago and found several markers distinguishing fetal from maternal cells in blood. But its priorities shifted and recently it licensed the technology to Vysis, which has been doing chromosomal analysis of fetal cells gleaned from amniocentesis
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • BP Amoco PLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • BP PLC
  • Senior Management
  • John Buchanan, CFO
  • Contact Info
  • BP PLC
    Phone: (44) 20 7496 4000
    Britannic House,1 Finsbury Circus
    London, EC2M 7BA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register